Safe Harbor

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
The information provided on this site includes information which are forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are subject to a variety of risks and uncertainties and reflect Celldex's current views with respect to future events and financial performance. You can identify forward-looking statements by the use of the words "may," "will," "can," "anticipate," "assume," "should," "indicate," "would," "believe," "comtemplate," "expect," "seek," "estimate," "continue," "plan," "point to," "project," "predict," "could," "intend," "target," "potential," and other similar words and expressions which predict or indicate future events and trends to and which do not relate to historical matters. You should not rely on forward-looking statements, because they involve known and unknown risks, uncertainties and other factors, some of which are beyond the control of the Company. These risks, uncertainties and other factors may cause the actual results, performance or achievements of the Company to be materially different from the anticipated future results, performance or achievements expressed or implied by the forward-looking statements.

Some of the factors that might cause these differences include, but are not limited to: (1) the successful integration of the businesses, multiple technologies and programs of Celldex; (2) the ability to adopt Celldex’s APC Targeting Technology™ to develop new, safe and effective vaccines against oncology and infectious disease indications; (3) the ability to adapt Celldex’s vectoring systems to develop new, safe and effective orally administered vaccines against disease causing agents; (4) the ability to successfully complete product research and further development, including animal, preclinical and clinical studies, and commercialization of CDX-110, CDX-1307, CDX-1401, CDX-011, CDX-1135 and other products and Celldex’s expectations regarding market growth; (5) the cost, timing, scope and results of ongoing safety and efficacy trials of CDX-110, CDX-1307, CDX-1401, CDX-011, CDX-1135 and other preclinical and clinical testing; (6) the ability to negotiate strategic partnerships or other disposition transactions for Celldex’s cardiovascular programs, including TP10 and CETi; (7) the ability of Celldex to manage multiple clinical trials for a variety of product candidates; (8) GlaxoSmithKline’s, or Glaxo’s, process of obtaining regulatory approval for the sale of Rotarix® in additional commercial markets, as well as the timing and success of worldwide commercialization of Rotarix® by Glaxo, which is not within our control; (9) Glaxo’s strategy and business plans to launch and supply Rotarix® worldwide, including in the U.S. and other major markets, which is not within our control, and its payment of royalties to Celldex; (10) Celldex’s expectations regarding its technological capabilities and expanding its focus to broader markets for vaccines; (11) changes in existing and potential relationships with corporate collaborators; (12) the availability, cost, delivery and quality of clinical and commercial grade materials produced at Celldex’s own manufacturing facility or supplied by contract manufacturers and partners; (13) the timing, cost and uncertainty of obtaining regulatory approvals for product candidates; (14) Celldex’s ability to develop and commercialize products before competitors that are superior to the alternatives developed by such competitors; (15) Celldex’s ability to retain certain members of management;(16) Celldex’s expectations regarding research and development expenses and general and administrative expenses; (17) Celldex’s expectations regarding cash balances, capital requirements, anticipated royalty payments (including those from Paul Royalty Fund), revenues and expenses, including infrastructure expenses; (18) the ability to obtain substantial additional funding; (19) Celldex’s belief regarding the validity of our patents and our ability to avoid potential intellectual property litigation, which can be costly and divert management time and attention; and (20) certain other factors that might cause Celldex’s actual results to differ materially from those in the forward-looking statements including those set forth under the headings “Business, Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations” in each of Celldex’s Annual Report on Form 10-K, its current Reports on Form 8-K, as well as those described in Celldex’s other press releases and filings with the Securities and Exchange Commission, from time to time. You should carefully review all of these factors, and you should be aware that there may be other factors that could cause these differences.

This site contains information concerning Celldex that may be useful to our suppliers, employees and shareholders as well as the general public. Celldex makes no representations or warranties as to the accuracy of the information contained on the site. Further, Celldex expressly disclaims any duty to do so. Celldex assumes no liability or responsibility for any errors or omissions in the content of the site or to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.